ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 189.5 | 96.4 | 108.1 |
| Other income | -0.4 | 4.2 | 7.5 |
| Total income | 189.0 | 100.6 | 115.6 |
| Profit before exceptional items & tax | 1.3 | 0.9 | 1.6 |
| Profit before tax | 1.3 | 0.9 | 1.6 |
| Net profit | 1.6 | 0.6 | 0.5 |
| Operating margin | 0.7% | 0.9% | 1.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +220.00% |
|---|---|
| Net profit, quarter on quarter | +166.70% |
| Revenue, year on year | +75.30% |
BSE results filing, NSE: AAREYDRUGS. Figures extracted from the filing.
Aarey Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹108.50
- Market cap
- ₹307.6 Cr
- Revenue (annual)
- ₹472.3 Cr
- Net profit (annual)
- ₹3.97 Cr
- P/E (TTM)
- 73.7×Sector 43.8×
- Promoter holding
- 41.45%+3.74% QoQ
- FII holding
- 4.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarey Drugs & Pharmaceuticals Ltd
All →Aarey Drugs & Pharmaceuticals Board Meeting Date
Aarey Drugs schedules a 14 November 2026 board meeting to approve unaudited half-year results. Trading window stays closed until 48 hours after results.
Aarey Drugs & Pharmaceuticals Other Announcement
Aarey Drugs & Pharmaceuticals Ltd filed its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI regulations.
Aarey Drugs & Pharmaceuticals Capital Structure Change
Aarey Drugs approved allotment of 1,150,000 equity shares from warrant conversion at ₹47.85 each, receiving ₹5.50 Crore. Issued capital rises to 31,874,303 shares.
- Value
- ₹5.50 Cr
Aarey Drugs & Pharmaceuticals Capital Structure Change
Promoter and promoter group of Aarey Drugs & Pharmaceuticals Ltd acquired 23.70 lakh shares following the conversion of warrants. The acquisition increased their stake by 4.81%.
- Promoter stake change
- +4.81%
Aarey Drugs & Pharmaceuticals Capital Structure Change
Aarey Drugs allotted equity shares to promoters following the conversion of 23,40,000 warrants. This capital structure change increases the promoters' equity stake in the company.
- Value
- ₹11.20 Cr
Aarey Drugs & Pharmaceuticals Annual General Meeting
Aarey Drugs & Pharmaceuticals Ltd. held its 36th Annual General Meeting on September 30, 2026, to conduct business including financial statement adoption and director re-appointment.